Preclinical
The American Academy of Neurology Virtual Annual Meeting 2021 is ongoing from April 17 through 22, with literally hundreds of presentations. Here’s a peek at just some of them.
Will We Need COVID-19 Vaccines Every Year? Although the jury is still out, a study out of Charité – Universitätsmedizin Berlin suggests that the answer is yes for a few years, but may be unnecessary after a few years post-pandemic.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for March 23, 2021.
The results published in the NEJM state that pegcetacoplan met the study’s primary endpoint for efficacy, demonstrating an advantage over eculizumab with a statistically significant improvement in adjusted means of 3.8 g/dL of hemoglobin at week 16 (p<0.001). An impressive 85% of patients were transfusion free at 16 weeks, in contrast to only 15% of eculizumab-treated patients.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for March 2, 2021.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for February 2, 2021.
Elevian believes that this single protein, a key player in the circulatory system, could be a game-changer in regenerative medicine.
While the ATLAS platform has the potential to lead to an effective vaccine in itself, its greatest impact in the field of immunotherapy may be that it offers a new way of understanding how a tumor evades the therapy’s boundaries by identifying bad Inhibigens that lead to suppressive, or inhibitory, responses.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for January 26, 2021.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for January 19, 2021.
PRESS RELEASES